ArticleFrontiers in reproductive health2025
Global trends and health system impact on polycystic ovary syndrome: a comprehensive analysis of age-stratified females from 1990 to 2021.
Article in Frontiers in reproductive health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Prevalence of polycystic ovary syndrome and determinants of knowledge among women in the eastern province Saudi Arabia.Frontiers in reproductive health · 2026Article
- Health-related quality of life in women with normogonadotropic ovulatory dysfunction: a prospective cohort study.Frontiers in global women's health · 2026Article
- Article
- Identifying Potential Drivers of the Polycystic Ovary Syndrome Burden in the European Union: GBD 2023 SEV Exposure Profiling and Mendelian Randomization.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a major factor in female infertility. The global burden of PCOS has generally been neglected due to insufficient data. This study aims to comprehensively assess the burden of PCOS among females aged 10-54 years globally from 1990 to 2021, to project trends for the next two decades, and to evaluate the impact of health system levels on PCOS prevalence. The incidence, prevalence, and disability-adjusted life years (DALYs) from the Global Burden of Disease (GBD) 2021 were analyzed, including global, sociodemographic index (SDI), GBD regions, health system levels, and national data. PCOS global burden escalated by 28% from 1990 to 2021. In 2021, the estimated annual percentage changes (EAPC) value of age-standardized rate of prevalence (ASPR), incidence, and DALYs were 0.77 (95% CI: 0.75-0.79), 0.74 (95% CI: 0.70-0.77), and 0.72 (95% CI: 0.68-0.75), respectively. High SDI regions showed elevated prevalence but slower growth (EAPC = 0.09) vs. low SDI regions, which exhibited the highest acceleration (EAPC = 1.23). Especially, the incidence and prevalence in the advanced health system were highest, but the most dramatic upward trend was observed in the basic level. The top three countries for ASPR were Italy (8,113.16 per 100,000 females, 95% CI: 5,757.74-11,265.85), Japan (6,334.11 per 100,000 females, 95% CI: 4,579.73-8,798.66), and New Zealand (5,689.13 per 100,000 females, 95% CI: 4,094.50-7,762.63). The incidence in adolescents aged 10-19 years was highest, warranting particular concern. This study underscored that health systems and adolescents require attention and strengthening as critical measures to control PCOS globally and to increase the fertility of women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.